Management of Osteoporosis in Adults with Cystic Fibrosis

Drugs

Volumn 64, Issue 2, 2004, Pages 133-147

  Hecker, Travis M ^a   Aris, Robert M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ADEKS; ALENDRONIC ACID; ALPHA TOCOPHEROL; ALUMINUM DERIVATIVE; ANABOLIC AGENT; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CAFFEINE; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CYTOKINE; ERGOCALCIFEROL; ETIDRONIC ACID; FUROSEMIDE; GLUCOCORTICOID; GROWTH HORMONE; IBANDRONIC ACID; IMMUNOSUPPRESSIVE AGENT; MEDROXYPROGESTERONE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RETINOL; RISEDRONIC ACID; SEX HORMONE; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP;

ABSORPTION; ADULT; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE PAIN; CALCIUM ABSORPTION; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYSTIC FIBROSIS; DELAYED PUBERTY; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FEVER; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GENETIC DISORDER; GRAFT REJECTION; GROWTH DISORDER; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; KYPHOSIS; LIFESPAN; LUNG TRANSPLANTATION; NUTRITION; NUTRITIONAL DEFICIENCY; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANCREAS INSUFFICIENCY; PATHOPHYSIOLOGY; PHLEBITIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REFLUX ESOPHAGITIS; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; TOBACCO; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; CLINICAL TRIALS; CYSTIC FIBROSIS; DIPHOSPHONATES; HUMAN GROWTH HORMONE; HUMANS; OSTEOPOROSIS; TERIPARATIDE; VITAMIN D; VITAMIN K;

NICOTIANA TABACUM;

EID: 0442307445     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464020-00002     Document Type: Review

References (74)

1. Hahn TJ, Squires AE, Halstead LR, et al. Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J Pediatr 1979; 94 (1): 38-42
2. Mischler EH, Chesney J, Chesney RW, et al. Demineralization in cystic fibrosis detected by direct photon absorptiometry. Am J Dis Child 1979; 133: 632-5
3. Bachrach LK, Loutit CW, Moss RB. Osteopenia in adults with cystic fibrosis. Am J Med 1994; 96: 27-34
4. Bhudhikanok GS, Wang MC, Marcus R, et al. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr 1998; 133: 18-27
5. Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr 1996; 128: 28-34
6. Haworth CS, Selby L, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54: 961-7
7. Laursen EM, Molgaard C, Michaelsen KF, et al. Bone mineral status in 134 patients with cystic fibrosis. Arch Dis Child 1999; 81 (3): 235-40
8. Salamoni F, Roulet M, Gudinchet F, et al. Bone mineral content in cystic fibrosis patients: correlation with fat-free mass. Arch Dis Child 1996; 74: 314-8
9. Grey AB, Ames RW, Matthews RD, et al. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993; 48: 589-93
10. Shaw N, Bedford C, Heaf D, et al. Osteopenia in adults with cystic fibrosis. Am J Med 1995; 99: 690-2
11. Conway S, Morton AM, Oldroyd B, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000; 55: 798-804
12. Registry CFF. Annual data base report. Bethesda (MD): Cystic Fibrosis Foundation, 2000
13. Hardin DS, Arumugan R, Seilheimer DK, et al. Normal bone mineral density in cystic fibrosis. Arch Dis Child 2001; 84: 262-8
14. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living to adulthood with cystic fibrosis. Ann Intern Med 1998; 128: 186-93
15. Elkin SL, Fairney A, Burnett S, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001; 12; 366-72
16. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001; 12: 22-7
17. Baroncelli GI, De Luca F, Maguzzu G, et al. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res 1997; 41: 397-403
18. Aris RM, Ontjes DA, Buell HE, et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporos Int 2002; 13: 151-7
19. Haworth CS, Selby L, Horrocks AW, et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002 Aug; 57 (8): 719-23
20. Elkin SL, Vedi S, Bord S, et al. Histomorphometric analysis of bone biopsies from the Iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 2002 Dec; 166 (11): 1470-4
21. Haworth CS, Webb AK, Egan JJ, et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000 Aug; 118 (2): 434-9
22. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18): 1187-91
23. Aris RM, Neuringer I, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109: 1176-83
24. Jelalian E, Stark LJ, Reynolds L, et al. Nutrition intervention for weight gain in cystic fibrosis: a meta analysis. J Pediatr 1998; 132 (3 Pt 1): 486-92
25. Lark RK, Lester GE, Ontjes DA, et al. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr 2001; 73: 602-6
26. Boucher GF, Lands LC, Hay JA, et al. Activity levels and the relationship to lung function and nutritional status in children with cystic fibrosis. Am J Phys Med Rehabil 1997 Jul-Aug; 76 (4): 311-5
27. Lands LC, Heigenhauser CM, Jones NL. Analysis of factors limiting maximal exercise perflormance in cystic fibrosis. Clin Sci (Lond) 1992 Oct; 83 (4): 391-7
28. Gulmans VA, de Meer K, Brackel HJ, et al. Outpatient exercise training in children with, cystic fibrosis: physiological effects, perceived competence, and acceptability. Pediatr Pulmonol 1999 Jul; 28 (1):39-46
29. Ott SM, Aitken ML. Osteoporosis in patients with cystic fibrosis. Clin Chest Med 1998; 19: 555-67
30. Haslam RH, Borovnicar DJ, Stroud DB. et al. Correlates of prepubertal bone mineral density in cystic fibrosis. Arch Dis Child 2001; 85 (2): 166-71
31. Stead RJ, Hodson ME, Batten JC, et al. Amenorrhoea in cystic fibrosis. Clin Endocrinol (Oxf) 1987; 26 (2): 187-95
32. Landon C, Rosenfeld RG. Short stature and pubertal delay in male adolescents with cystic fibrosis: androgen treatment. Am J Dis Child 1984; 138 (4): 388-91
33. Moshang T, Holsclaw Jr DS. Menarchal determinants in cystic fibrosis. Am J Dis Child 1980; 134 (12): 1139-42
34. Alemzadeh R, Upchurch L, McCarthy V. Anabolic effects of growth hormone treatment in young children with cystic fibrosis. J Am Coll Nutr 1998 Oct; 17 (5): 419-24
35. Hardin DS. Growth problems and growth hormone treatment in children with cystic fibrosis. J Pediatr Endocrinol Metab 2002 May; 15 Suppl. 2: 731-5
36. Johannesson M, Landgren BM, Csemiczky G, et al. Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Hum Reprod 1998; 13 (8): 2092-7
37. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxf) 2003 May; 42 Suppl. 2: ii11-6
38. Grey A, Mitnick MA, Shapses S, et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption - a clinical research center study. J Clin Endocrinol Metab 1996 Oct; 81: 3450-4
39. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Engl J Med 1995; 332: 305-11
40. Aris RM, Stephens AR, Ontjes DA, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000 Nov: 162: 1674-8
41. McColley SA, Stellmach V, Boas SR, et al. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000 Jun; 161 (6): 1877-80
42. Sambrook N. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000; 15: 1645-9
43. Flohr F, Lutz A, App EM, et al. Bone mineral density and quantitative ultrasound in adults with cystic fibrosis. Eur J Endocrinol 2002; 146 (4): 531-6
44. Tschopp O, Boehler A, Speich R, et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2002; 2 (2): 167-72
45. Dubois EF, Roder E, Dekhuijzen PN, et al. Dual x-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest 2002; 121 (5): 1456-63
46. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry annual data report. Bethesda (MD): Cystic Fibrosis Foundation, 2001
47. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996; 101: 262-9
48. Ferrari SL, Nicod L, Hamacher J, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J 1996; 9 (11): 2378-82
49. Spira A, Gutierrez C, Chaparro C, et al. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117 (2): 476-81
50. Hanly JG, McKenna MJ, Quigley C, et al. Hypovitaminosis D and response to supplementation in older patients with cystic fibrosis. Q J Med 1985; 56 (219): 377-85
51. Kelly E, Marsh R, Pencharz P, et al. Effect of Vitamin D supplementation on low serum 25-hydroxyvitamin D in adults with cystic fibrosis [abstract no. 478]. Pediatr Pulmonol 2002; 24 Suppl.: 344
52. Ontjes DA, Lark RK, Lester GE, et al. Vitamin D depletion and replacement in patients with cystic fibrosis. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D endocrine system: structural, biological, genetic and clinical aspects. Riverside (CA): University of California, 2000: 893-6
53. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-56
54. Brown SA, Ontjes DA, Lark RK, et al. Short-term calcitriol administration improves calcium homeostasis in adults with CF. Osteoporosis Int 2003; 14 (5): 442-9
55. Enfissi L, Bianchi ML, Galbiati E, et al. Osteoporosis in CF: calcifediol therapy increases bone mineral density (BMD) [abstract no. 475]. Pediatric Pulm 2001; 22 Suppl.: 334
56. Itioue T, Sugiyarna T, Matsubara T, et al. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 treatment in children treated with glucocorticoid and alfacalcidol. Endocr J 2001; 48: 11-8
57. Shiraki M, Shiraki Y, Aoki C, et al. Vitamin K2 effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000; 15: 515-21
58. Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press, 2001
59. Aris RM, Brown SA, Oritjes DA, et al. Reduced carboxylated osteocilcin levels in cystic fibrosis [letter]. Am J Respir Crit Care Med 2003 Nov 1; 168 (9): 1129
60. de Groen C, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996 Oct 3; 335 (14): 1016-21
61. Shnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis: Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12 (1): 1-12
62. Aris RM, Lester GE, Renner RB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000; 162 (3 Pt 1): 941-6
63. Haworth CS, Selby L, Adams JE, et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56 (4): 314-6
64. Haworth CS, Selby L, Webb AK, et al. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998; 352 (9142): 1753-4
65. Haworth CS, Selby L, Webb AK, et al. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis [letter]. Lancet 1999; 353 (9167): 1886
66. Saag KG, Emkey R, Schnitzer TJ, et al. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339 (5): 292-9
67. Aris RM, Lester GE, Camniti M, et al. Efficacy of alendronate in cystic fibrosis adults with low bone density [online]. Available from URL: http://ajrccm.atsjournals.org/articlesin-press.shtml [Accessed 2003 Dec 5]. Am J Respir Crit Care Med. Epub 2003 Oct 16
68. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997 Aug 7; 337 (6): 382-7
69. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Post-menopausal Osteoporosis. Endocr Pract 2001 Jul-Aug; 7 (4): 293-312
70. Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001; 139 (5): 636-42
71. Hardin DS, Stratton R, Kramer JC, et al. Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Horm Metab Res 1998; 30 (10): 636-41
72. Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone decreases protein catabolism in children with cystic fibrosis. J Clin Endocrinol Metab 2001; 86 (9): 4424-8
73. Hardin DS, Rice J. Growth hormone improves bone mineral content in prepubertal and adolescent children with CF [abstract no. 456]. Pediatr Pulmonol 2002; 24 Suppl.: 336
74. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in post-menopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87 (10): 4528-35